|
KMID : 0370220160600030118
|
|
Yakhak Hoeji
2016 Volume.60 No. 3 p.118 ~ p.127
|
|
|
ABCB1 Polymorphisms and Imatinib Response in Chronic Myeloid Leukemia Patients: Systematic Review and Meta-analysis
|
|
Ha Hye-Min
Chun Pu-Soon
|
|
|
Abstract
|
|
|
|
A growing number of studies have demonstrated that ABCB1 gene polymorphisms are associated with the variability of responses to imatinib. However, the effects of ABCB1 polymorphisms on imatinib response in chronic myeloid leukemia (CML) are inconsistent. The aim of the present study was to clarify the associations between ABCB1 polymorphisms and imatinib response in CML. A systematic literature review was performed. The databases of PubMed, Embase, and Cochrane Library were searched for all published studies from inception to December 2015. The following terms were used with functions of ‘AND’ and ‘OR’: ‘chronic myeloid leukemia’, ‘CML’, ‘ABCB1’, ‘MDR1’, ‘polymorphism’, ‘SNP’, and ‘imatinib’. Using the Review Manager 5, odds ratios (ORs) were pooled to estimate the effect of ABCB1 polymorphisms on imatinib response in CML. The pooled analysis showed that ABCB1 2677 G allele was significantly associated with poor response to imatinib in African and Asian patients (GG vs TT, OR: 0.32, p<0.0001; GG+GT vs TT, OR: 0.44, p=0.0005). In subgroup analyses, African patients carrying ABCB1 1236 C allele exhibited higher risk for worse response, whereas Asian patients with 1236 C allele showed better response (CC+CT vs TT, OR: 0.41, p=0.008 for African; OR: 1.65, p=0.03 for Asian). There was no association between C3435T polymorphisms and imatinib response in African, Asian, and Caucasian CML patients.
|
|
|
KEYWORD
|
|
|
ABCB1 C1236T polymorphism, ABCB1 G2677T polymorphism, ABCB1 C3435T polymorphism, chronic myeloid leukemia, imatinib, response
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|